Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Cash flows from operating activities
Net loss	$ (111,545)	$ (38,861)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of property and equipment	130	197
Amortization of platform development and intangible assets	7,227	13,996
Amortization of debt discounts	596	1,645
Noncash and accrued interest	5,959	602
Loss on impairment of assets	40,589	119
Change in fair value of contingent consideration	313	409
Liquidated damages	152	304
Stock-based compensation	1,976	12,616
Deferred income taxes	62	73
Bad debt expense	672	54
Other	(21)
Change in operating assets and liabilities net of effect of business combination:
Accounts receivable, net	20,458	2,213
Subscription acquisition costs	6,131	(7,273)
Prepayments and other current assets	1,043	(7,327)
Other long-term assets	230	8
Accounts payable	(3,645)	742
Accrued expenses and other	41,155	(800)
Unearned revenue	(14,304)	5,526
Subscription refund liability	105	45
Operating lease liabilities	(524)	(114)
Contingent consideration	(1,683)
Other long-term liabilities	(237)	(574)
Net cash used in operating activities	(5,161)	(16,400)
Cash flows from investing activities
Purchases of property and equipment	(27)
Capitalized platform development	(1,485)	(2,132)
Payments for acquisition of business, net of cash acquired		(500)
Net cash used in investing activities	(1,512)	(2,632)
Cash flows from financing activities
Payment of Fexy put option	(561)
(Repayments) proceeds under line of credit, net borrowing	(20,027)	815
Proceeds from common stock private placement	12,000
Proceeds from Simplify loan	12,748
Proceeds from common stock registered direct offering		11,500
Payments of issuance costs from common stock registered direct offering		(167)
Payment of deferred cash payments	(200)	(75)
Payment of taxes from common stock withheld	(486)	(1,423)
Net cash provided by financing activities	3,474	10,650
Net decrease in cash, cash equivalents, and restricted cash	(3,199)	(8,382)
Cash, cash equivalents, and restricted cash – beginning of period	9,284	14,373
Cash, cash equivalents, and restricted cash – end of period	6,085	5,991
Cash, cash equivalents, and restricted cash
Cash and cash equivalents	6,085	5,489
Restricted cash		502
Total cash, cash equivalents, and restricted cash	6,085	5,991
Supplemental disclosure of cash flow information
Cash paid for interest	2,033	7,140
Cash paid for income taxes	85	85
Noncash investing and financing activities
Reclassification of stock-based compensation to platform development	228	548
Issuance cost of registered direct offering recorded in accrued expenses and other		189
Repurchase of common stock for Fexy put option	379
Issuance of common stock in connection with settlement of liquidated damages		499
Issuance of common stock upon conversion of Series H convertible preferred stock		1,500
Issuance of common stock in connection with acquisition		2,000
Deferred cash payments recorded in connection with acquisitions		246
Reclassification to liability upon common stock modification		$ 68